Neurology
🇺🇸 FDA Page 4FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Gain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Showing 37–48 of 63 articles
CorTec's Brain Interchange™ BCI System Accepted into FDA Total Product Life Cycle Advisory Program for Stroke Rehabilitation
AbbVie Receives FDA Complete Response Letter for TrenibotulinumtoxinE (TrenibotE) Manufacturing Issues
Capricor Therapeutics HOPE-3 Phase 3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy to be Presented at AAN 2026
Neurosterix NTX-253 Schizophrenia Drug Phase 1 Trial on Track for Q2 2026 Completion
ClearPoint Neuro Receives FDA Clearance for Velocity Alpha MR High Speed Surgical Drill System
Alterity Therapeutics ATH434 Shows Reduced Functional Decline in Multiple System Atrophy Phase 2 Trial
Neurosterix NTX-253 Phase 1 Schizophrenia Trial On Track for Q2 2026 Completion
NRx Pharmaceuticals Receives Positive FDA Feedback on Preservative-Free Ketamine Generic Drug Application
Denali Therapeutics Receives FDA Approval for Avlayah (Tividenofusp Alfa) to Treat Hunter Syndrome
Capricor Therapeutics Presents Phase 3 HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy at AAN 2026
Ractigen Therapeutics RAG-17 Shows 81% Reduction in ALS Biomarker in Phase I Trial
NRx Pharmaceuticals Receives Positive FDA Feedback on Preservative-Free Ketamine Generic Drug Application